Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia - Wikidata - wikimedia - TriplyDB

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

http://www.wikidata.org/entity/Q26781539

about

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Challenges of development and implementation of point of care pharmacogenetic testing.ρ⁰ Cells Feature De-Ubiquitination of SLC Transporters and Increased Levels and Fluxes of Amino Acids.Toward Precision Medicine: How Far Is the Goal?The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.

P2860

Q33577088-0D19B8FC-BFB8-40B2-992D-A92DF7F662C0 Q37190128-DABBBD19-028B-4CA1-A901-8B868579FED6 Q37685527-ECC53BF5-3A5B-44C9-879D-1F3C63263997 Q38826494-62A76124-E3D0-40F6-9162-FA8535AA8FC9 Q39611892-1B4F4100-96AC-48A2-97E3-0EF477223BEC Q42289968-2D7C628B-25AB-4BD9-81D3-2704CB83FDC4 Q42672408-618E1F56-522A-485D-92DC-123B0F56DCC3 Q45790127-EB5F8EFA-3DE6-4A2D-A501-FE3C9161FD64 Q47912945-0DABCF7B-3880-4DA9-B3D3-3863EB4244F2

P2860

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

http://www.wikidata.org/entity/Q26781539

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@ast

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@en

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@nl

type

label

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@ast

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@en

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@nl

prefLabel

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@ast

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@en

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@nl

P1433

Q26781539-F55C72E7-F371-4FC8-A7E4-EF00003A2F2F

P1476

Q26781539-9BA892E0-43E8-4399-8BE0-9EF42B665D77

P2093

Q26781539-0FB452AE-635E-42A2-AE5F-ADA0CE25C48C

Q26781539-78FD42FF-AA86-4AF3-A651-3E9BB4EAF49D

Q26781539-7C5A3EF3-A06B-4F0A-ACE3-FB36D38D45C0

Q26781539-9AD7B7FE-A2C8-46D9-B979-6D8BF7BA290D

Q26781539-B2286D22-FD87-4D66-8B1C-6D760DD6183C

P275

Q26781539-330CCD62-AF3F-41BA-B09B-54E3101C234F

P2860

Q26781539-0087B6FE-5421-445C-8D44-60CF0E621021

Q26781539-084CBEE3-E2D0-417C-A5B4-CCAC80348C0B

Q26781539-0D7D9D3E-E7C3-4D96-948D-4AE0D33895AB

Q26781539-0EB36069-FACC-442F-9ACE-9DC93E2E94B3

Q26781539-0FA03CA6-D127-48CC-A5DA-97D049BB3316

Q26781539-1266A478-1280-4604-BC71-BCAA8EAFE66A

Q26781539-1284527C-E659-4039-983E-2A07C324DE0A

Q26781539-14047058-D56D-4373-8697-266F129631FA

Q26781539-146F6BCC-20DA-4B25-9A24-BA714E45BB95

Q26781539-1E6B030C-83FE-4130-BC47-1842A283E15B

P304

Q26781539-6F061DF3-E1CC-4586-BD1B-5A34D02D1BF1

P31

Q26781539-842AE18D-0DA5-4297-A644-9C652C797E0D

P356

Q26781539-E2CD1C42-3E11-42F2-AE8B-710920948E10

P407

Q26781539-737F3D98-BA8B-4A51-A3CE-7409C78E90E8

P433

Q26781539-62399295-8D84-48EB-B7E6-1C90A580C7C9

P478

Q26781539-BC16DB0E-97AD-42F5-A41D-C769E209B858

P50

Q26781539-C3E983BC-612D-4942-A929-D3441E558DB2

P5008

Q26781539-37418A09-ABA0-4C8D-ADE8-1337D953D14B

P577

Q26781539-2B5FB96D-1F37-41F1-9D49-70DEC387C5AD

P5875

Q26781539-8E14998C-8445-4B93-84C2-E03F593733B7

P698

Q26781539-CB8F33DB-3F92-4882-90CD-77081ADBF57E

P921

Q26781539-129C402B-2803-412F-ACB9-09AE619D36EC

Q26781539-1D2B406B-3C7B-4C5B-8C37-438C37F5E09C

Q26781539-6204861D-0F95-42BF-A7D7-D0AE51839FF3

Q26781539-80D94B9E-FE69-4537-A4F9-E7F3B2986B17

Q26781539-8C8719DC-7C1D-48D8-BF97-9E48FE956A30

Q26781539-8D953A76-6974-416F-8CBF-8EC8EBEA7FC0

Q26781539-933D99F4-BA8A-4B14-925C-089C07962201

Q26781539-DCD41776-EBE8-42E5-A3CC-D0C542FE82F0

Q26781539-F124E138-E292-428D-848A-901731F4D0B7

Q26781539-FB93F54A-5597-4DED-A91C-9235046D6F71

P932

Q26781539-79C4EF3A-2A80-44E0-92D6-2E1F4D71F655

P356

P1433

International Journal of Molecular Sciences

P1476

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

@en

P2093

Antonello Di Paolo

http://www.w3.org/2001/XMLSchema#string

Claudia Baratè

http://www.w3.org/2001/XMLSchema#string

Marialuisa Polillo

http://www.w3.org/2001/XMLSchema#string

Mario Petrini

http://www.w3.org/2001/XMLSchema#string

Sara Galimberti

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene

Metabolism considerations for kinase inhibitors in cancer treatment

Active transport of imatinib into and out of cells: implications for drug resistance.

SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins

Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.

P304

22811-22829

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS160922811

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2015-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282153610

http://www.w3.org/2001/XMLSchema#string

P698

26402671

http://www.w3.org/2001/XMLSchema#string

P921

Aagianik kimischri

pharmacogenetics

mechanism of action

proto-oncogene proteins

neoplasm proteins

mutant proteins

chronic myeloid leukemia

P932

4613337

http://www.w3.org/2001/XMLSchema#string